Anti-amyloid Alzheimer’s drugs show no clinically meaningful effect
People with Alzheimer’s disease have high levels of a protein known as amyloid beta in their brains, detectable before symptoms begin, but its role in disease progression is uncertain. Drugs…
New data on effective cardiac resynchronisation in patients with heart failure
Left bundle branch area pacing was found to be an effective and practical strategy for cardiac resynchronisation, according to a Late-Breaking Science presentation at EHRA 2026,1 the annual congress of…
Can a new heart health metric identify fracture risk in postmenopausal women?
Postmenopausal women face a high risk of bone fractures. Due to declines in estrogen levels, which can lead to an increased risk of osteoporosis, even a low-impact fall can result…
Nearly 30% of patients with resistant hypertension have a hormone disorder caused by high cortisol
Resistant hypertension is a condition where blood pressure stays high even though patients take three or more different blood pressure medications. This impacts nearly 10 million patients with high blood…
500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause
A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable Fezolinetant (Veoza*) is recommended to…
Targeted cholesterol-lowering therapy can prevent first heart attack or stroke in high-risk patients with diabetes
Mass General Brigham researchers found that the intensive cholesterol‑lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high‑risk patients who did not have known atherosclerosis (the…
EHRA 2026: Shining a light on arrhythmia management
The global community of heart rhythm specialists will unite in Paris from 12 to 14 April 2026 for EHRA 2026, the annual congress of the European Heart Rhythm Association (EHRA),…
Thymidine Kinase 2 Deficiency (TK2d): European Commission approves doxecitine and doxribtimine (KYGEVVI®) as first and only treatment
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances for KYGEVVI (doxecitine and doxribtimine) for the treatment…
Sepsis linked to nearly 1 in 5 pediatric hospital deaths in the US
Nearly 1 in 5 pediatric hospital deaths in the United States involve sepsis, according to a new national study published March 22 in JAMA. The study also found that sepsis…
How you walk could help doctors tell two similar brain diseases apart
Doctors often struggle to distinguish early dementia with Lewy bodies from early Parkinson’s disease. The two neurological conditions share many symptoms, including changes in movement, and are frequently misdiagnosed in…